Online citations, reference lists, and bibliographies.
← Back to Search

Influence Of Dose And Immunization Route On The Serum Ig G Antibody Response To BSA Loaded PLGA Microspheres.

I. Gutierro, R. Hernández, M. Igartua, A. R. Gascón, J. Pedraz
Published 2002 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
BSA was entrapped into PLGA 50:50 microspheres and the in vitro release study was performed. Then 1 microg of microencapsulated antigen was subcutaneously administered to Balb/c mice and the serum Ig G response was compared to that obtained after the subcutaneous administration of the same amount of only free antigen or of free antigen emulsified 1:1 with Freund's complete adjuvant (FCA). The specific serum Ig G responses obtained from the microencapsulated antigen were higher than those obtained from the free antigen and similar to those obtained from the antigen emulsified with FCA. Therefore, the immune response obtained with the subcutaneous administration of 1 microg of microencapsulated antigen was used as a positive control to compare the immune response elicited by the administration of the spheres either by the oral or the intranasal route. There is a dose/response relationship in the serum Ig G response elicited after three consecutive oral administrations of microencapsulated antigen at a dosing range from 200 to 50 microg. However, this relationship does not seem to be clear for the intranasal administration of the spheres at the same dosing range. When comparing the serum Ig G responses at each dosing level for the different routes of administration, it can be observed that the intranasal route is a more powerful inducer of the production of specific Ig G antibody than the oral, which could be due to a greater permeability of the nasal epithelium and to qualitative differences between the mechanisms of induction of the immune response by each route. The serum Ig G2a versus Ig G1 ratio is not significantly different among all the groups that received antigen in microspheres.
This paper references
10.1146/ANNUREV.IMMUNOL.15.1.297
Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches.
S. Constant (1997)
10.1128/IAI.69.8.4767-4773.2001
Facilitated Intranasal Induction of Mucosal and Systemic Immunity to Mutans Streptococcal Glucosyltransferase Peptide Vaccines
D. Smith (2001)
10.1016/S0169-409X(98)00045-3
Microparticles and polymers for the mucosal delivery of vaccines.
O’Hagan (1998)
10.1016/S0264-410X(98)00256-4
Evaluation of novel aggregate structures as adjuvants: composition, toxicity studies and humoral responses.
P. Rajananthanan (1999)
10.1016/S0169-409X(98)00040-4
Specific and non-specific bioadhesive particulate systems for oral delivery to the gastrointestinal tract.
Ponchel (1998)
10.1146/ANNUREV.IMMUNOL.18.1.593
The role of chemokine receptors in primary, effector, and memory immune responses.
F. Sallusto (2000)
10.1095/BIOLREPROD44.3.491
Langerhans cells and T lymphocyte subsets in the murine vagina and cervix.
M. Parr (1991)
10.1146/ANNUREV.IMMUNOL.14.1.275
Antigen sampling across epithelial barriers and induction of mucosal immune responses.
M. Neutra (1996)
10.1016/S0169-409X(98)00043-X
Microparticle targeting to M cells.
Ermak (1998)
10.1002/EJI.1830240710
Immunoglobulin isotype regulation by antigen‐presenting cells in vivo
G. De Becker (1994)
10.1073/PNAS.94.23.12551
Dendritic cell ontogeny: a human dendritic cell lineage of myeloid origin.
J. Olweus (1997)
10.1046/j.1440-1711.1998.00743.x
Polymer‐grafted starch microparticles for oral and nasal immunization
M. Mcdermott (1998)
10.1046/j.1523-5378.1999.09046.x
Oral Immunization with Helicobacter pylori‐Loaded Poly( d, l‐Lactide‐Co‐Glycolide) Nanoparticles
S. Kim (1999)
10.1023/A:1016085108889
Gastrointestinal Uptake of Biodegradable Microparticles: Effect of Particle Size
M. P. Desai (2004)
10.1146/ANNUREV.IMMUNOL.18.1.767
Immunobiology of dendritic cells.
J. Banchereau (2000)
10.1006/CIMM.1997.1088
Iscoms containing purified Quillaja saponins upregulate both Th1-like and Th2-like immune responses.
A. Sjölander (1997)
10.1016/S0264-410X(01)00192-X
Biodegradable PLGA microspheres as a delivery system for malaria synthetic peptide SPf66.
J. Rosas (2001)
10.1016/S0264-410X(01)00110-4
Intranasal immunisation with influenza-ISCOM induces strong mucosal as well as systemic antibody and cytotoxic T-lymphocyte responses.
S. Sjölander (2001)
Particle uptake and translocation across epithelial membranes.
N. W. Thomas (1996)
The interaction of murine IgG subclass proteins with human monocyte Fc receptors.
M. Lubeck (1985)
10.1016/S0939-6411(97)00056-8
Development and characterization of protein-loaded poly(lactide-co-glycolide) nanospheres
M. D. Blanco (1997)
10.1016/S0165-2478(00)00188-7
Antigen dose defines T helper 1 and T helper 2 responses in the lungs of C57BL/6 and BALB/c mice independently of splenic responses.
T. Morokata (2000)
10.1201/9781003067542-2
INJECTABLE BIODEGRADABLE MICROSPHERES FOR VACCINE DELIVERY
T. Kissel (1996)
10.1016/S0264-410X(97)00248-X
Enhancement of immune response to intranasal influenza HA vaccine by microparticle resin.
M. Higaki (1998)
10.1679/AOHC.52.231
An immuno-electron microscopic study on interactions among dendritic cells, macrophages and lymphocytes in the human palatine tonsil.
S. Okato (1989)
Towards a multipurpose mucosal vaccination using phosphorylcholine as a unique antigen
S. Trollé (1998)
10.1016/S0169-409X(01)00197-1
Chitosan for mucosal vaccination.
I. M. van der Lubben (2001)
Langerhans cells, macrophages and lymphocyte subsets in the cervix and vagina of rhesus macaques.
C. Miller (1992)
10.1016/S0264-410X(00)00343-1
Towards clinical testing of a single-administration tetanus vaccine based on PLA/PLGA microspheres.
P. Johansen (2000)
10.1016/S0169-409X(98)00047-7
Oral particulate delivery: status and future trends.
Chen (1998)
10.1016/S0378-5173(98)00155-0
Peptide degradation during preparation and in vitro release testing of poly(l-lactic acid) and poly(dl-lactic-co-glycolic acid) microparticles
C. Witschi (1998)
Development of an oral drug delivery system targeting immune-regulating cells in experimental inflammatory bowel disease: a new therapeutic strategy.
H. Nakase (2000)
10.1016/S0264-410X(97)00249-1
Intra nasal administration of poly-lactic acid microsphere co-encapsulated Yersinia pestis subunits confers protection from pneumonic plague in the mouse.
J. Eyles (1998)
10.1201/9781003067542
Microparticulate systems for the delivery of proteins and vaccines
S. Cohen (1996)
10.1016/S0264-410X(98)00085-1
Oral administration of polymer-grafted starch microparticles activates gut-associated lymphocytes and primes mice for a subsequent systemic antigen challenge.
P. Heritage (1998)
10.1016/S0378-5173(99)00047-2
In vivo fate and immune pulmonary response after nasal administration of microspheres loaded with phosphorylcholine-thyroglobulin.
S. Trollé (1999)
10.1073/PNAS.85.21.8181
T helper cell subsets require the expression of distinct costimulatory signals by antigen-presenting cells.
C. Weaver (1988)
10.1163/156856299X00892
Intranasal immunization against influenza virus using polymeric particles.
D. Lemoine (1999)
10.3109/10611869609015965
Nasal delivery of vaccines.
A. Almeida (1996)
10.1016/S0378-5173(99)00239-2
Immunological responses to nasal delivery of free and encapsulated tetanus toxoid: studies on the effect of vehicle volume.
J. Eyles (1999)
10.1128/IAI.67.5.2643-2648.1999
Single-Dose Mucosal Immunization with Biodegradable Microparticles Containing a Schistosoma mansoniAntigen
B. Baras (1999)
10.1111/j.2042-7158.1996.tb05872.x
Prolonged Immune Response Evoked by a Single Subcutaneous Injection of Microcapsules Having a Monophasic Antigen Release
H. Sah (1996)
10.1093/AJCP/92.1.42
Plasmacytoid monocytes (so-called plasmacytoid T-cells) in Kikuchi's lymphadenitis. An immunohistologic study.
F. Facchetti (1989)
10.3109/02652049709051138
Influence of formulation variables on the in-vitro release of albumin from biodegradable microparticulate systems.
M. Igartua (1997)
Tonsillar epithelial dendritic cells. Demonstration by lectin binding, immunohistochemical characterization, and ultrastructure.
D. S. Weinberg (1987)
Nasal vaccines. From fundamental concepts to vaccine development
D. Lemoine (1998)
10.1038/32588
Dendritic cells and the control of immunity
J. Banchereau (1998)



This paper is referenced by
10.1016/j.intimp.2009.06.008
Induction of mucosal and systemic humoral immune responses in murine system by intranasal immunization with peptide antigens of P. vivax and CpG oligodeoxynucleotide (ODN) in microparticle delivery.
A. Bhat (2009)
10.1016/j.ejpb.2009.04.009
Targeting nanoparticles to M cells with non-peptidic ligands for oral vaccination.
V. Fiévez (2009)
10.1021/mp400589q
Delivery of polysaccharides using polymer particles: implications on size-dependent immunogenicity, opsonophagocytosis, and protective immunity.
C. Anish (2014)
10.1016/S0264-410X(02)00435-8
Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres.
I. Gutierro (2002)
10.1016/j.vaccine.2010.06.121
Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen.
B. Slütter (2010)
10.1201/B18096-3
Emerging Trends in Delivery of Novel Vaccine Formulations
Trinh Vo (2015)
10.1002/PAT.656
Synthesis and characterization of pendant carboxylic acid functional poly(lactic acid) and poly(lactic acid-co-glycolic acid) and their drug release behaviors
Nilhan Kayaman-Apohan (2005)
Strategy of oral vaccination by polymeric nanoparticles : M cell targeting or bioadhesion
Laurence Plapied (2011)
Evaluation of intranasal canine parvovirus vaccination in dogs
Murugesan (2010)
10.1016/j.jconrel.2016.02.014
Mucosal vaccine delivery: Current state and a pediatric perspective.
A. Shakya (2016)
10.1201/B20045-10
Overview of Methods of Making Polyester Nano- and Microparticulate Systems for Drug Delivery
M. Kumar (2017)
10.1016/J.VACCINE.2006.01.066
Immunogenicity and lower dose requirement of polymer entrapped tetanus toxoid co-administered with alum.
Y. Katare (2006)
10.1080/08982100600992302
Mannosylated Niosomes as Adjuvant-Carrier System for Oral Mucosal Immunization
S. Jain (2006)
10.1080/0265204031000093023
Immune responses to orally administered PLGA microparticles: influence of oil vehicles and surfactive agents
I. Gutierro (2003)
10.1016/J.VACCINE.2004.11.079
Activation of dendritic cells by microparticles containing Bacillus anthracis protective antigen.
A. Westwood (2005)
10.1080/1943085X.2010.488198
Applications of Nanotechnology in Vaccine Delivery
A. Singh (2010)
10.1016/J.JCONREL.2006.08.013
Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach.
A. des Rieux (2006)
10.1016/J.IJPHARM.2007.11.021
Enhanced immune response induced by BSA loaded in hydroxyethylstarch microparticles.
E. Balasse (2008)
10.4161/hv.23255
Epitope-specific immune recognition of the nontypeable Haemophilus influenzae outer membrane protein 26
D. Kunthalert (2013)
10.1007/s12033-014-9826-1
In planta Production of Flock House Virus Transencapsidated RNA and Its Potential Use as a Vaccine
Yiyang Zhou (2014)
10.1081/CNV-120023770
Local Delivery of IL-1α Polymeric Microspheres for the Immunotherapy of an Experimental Fibrosarcoma
J. Mullerad (2003)
10.1016/J.IJPHARM.2004.05.009
Evaluation of the clearance characteristics of various microspheres in the human nose by gamma-scintigraphy.
M. Tafaghodi (2004)
10.1016/J.IAC.2006.02.007
Biodegradable PLGA particles for improved systemic and mucosal treatment of Type I allergy.
I. Schoell (2006)
10.1016/J.VACCINE.2007.09.001
A genetically engineered prime-boost vaccination strategy for oculonasal delivery with poly(D,L-lactic-co-glycolic acid) microparticles against infection of turkeys with avian Metapneumovirus.
M. Liman (2007)
10.4236/WJV.2011.13011
Immune Augmentation of Injectable PLGA – Dextran (PLDEX) a Double Polymeric Microspheres as an Adjuvant for Hepatitis B Vaccine
Sivakumar Sivagurunathan Moni (2011)
Les propriétés adjuvantes des microcapsules d’hydroxyéthyl amidon. Application en immunothérapie anti-mélanome
E. Balasse (2007)
10.1002/JPS.10296
Thermal stability of vaccines.
D. Brandau (2003)
10.1016/j.jconrel.2013.05.019
Carbon nanotube-protein carriers enhance size-dependent self-adjuvant antibody response to haptens.
J. Parra (2013)
10.1016/J.IJPHARM.2005.05.028
Influence of particle size, antigen load, dose and additional adjuvant on the immune response from antigen loaded PLA microparticles.
Y. Katare (2005)
10.1016/J.VACCINE.2003.10.020
Potent, long lasting systemic antibody levels and mixed Th1/Th2 immune response after nasal immunization with malaria antigen loaded PLGA microparticles.
A. M. Carcaboso (2004)
10.7936/K78P5XPN
Sustained Dual Drug Delivery of Anti-Inhibitory Molecules for Spinal Cord Injury Treatment
T. Wilems (2015)
10.1016/j.jconrel.2015.06.031
Sustained dual drug delivery of anti-inhibitory molecules for treatment of spinal cord injury.
T. Wilems (2015)
See more
Semantic Scholar Logo Some data provided by SemanticScholar